These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21368851)

  • 1. Commentary: reaching women drug users with methadone treatment and other HIV prevention services in Tehran.
    Claeson M
    J Public Health Policy; 2011 May; 32(2):231-3. PubMed ID: 21368851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The establishment of a methadone treatment clinic for women in Tehran, Iran.
    Dolan K; Salimi S; Nassirimanesh B; Mohsenifar S; Mokri A
    J Public Health Policy; 2011 May; 32(2):219-30. PubMed ID: 21390074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran.
    Farnia M; Ebrahimi B; Shams A; Zamani S
    Int J Drug Policy; 2010 Sep; 21(5):422-4. PubMed ID: 20413287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Iranian women seeking drug treatment.
    Dolan K; Salimi S; Nassirimanesh B; Mohsenifar S; Allsop D; Mokri A
    J Womens Health (Larchmt); 2011 Nov; 20(11):1687-91. PubMed ID: 21905877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV, STD and hepatitis prevention among women in methadone maintenance: a qualitative and quantitative needs assessment.
    Morrow K; Costello T
    AIDS Care; 2004 May; 16(4):426-33. PubMed ID: 15203411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring stakeholder perceptions of facilitators and barriers to accessing methadone maintenance clinics in Yunnan Province, China.
    Philbin MM; Zhang F
    AIDS Care; 2010 May; 22(5):623-9. PubMed ID: 20229375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran.
    Zamani S; Farnia M; Tavakoli S; Gholizadeh M; Nazari M; Seddighi AA; Setayesh H; Afshar P; Kihara M
    Int J Drug Policy; 2010 May; 21(3):167-72. PubMed ID: 19395250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women drug users and HIV prevention: overview of findings and research needs.
    Stevens SJ; Tortu S; Coyle SL
    Women Health; 1998; 27(1-2):19-23. PubMed ID: 9640632
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictors of treatment retention in a major methadone maintenance treatment program in iran: a survival analysis.
    Pashaei T; Moeeni M; Roshanaei Moghdam B; Heydari H; Turner NE; Razaghi EM
    J Res Health Sci; 2014; 14(4):291-5. PubMed ID: 25503286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monitoring and evaluation of the Hungarian methadone maintenance programmes].
    Rácz J; Melles K; Márványkövi F; Vadász V
    Psychiatr Hung; 2010; 25(3):202-20. PubMed ID: 20884995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam.
    Lambers FA; Stolte IG; van den Berg CH; Coutinho RA; Prins M
    Int J Drug Policy; 2011 May; 22(3):210-8. PubMed ID: 21392958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating HIV education and counseling into routine prenatal care: a program model.
    Mason J; Preisinger J; Sperling R; Walther V; Berrier J; Evans V
    AIDS Educ Prev; 1991; 3(2):118-23. PubMed ID: 1873135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A transitional opioid program to engage hospitalized drug users.
    Shanahan CW; Beers D; Alford DP; Brigandi E; Samet JH
    J Gen Intern Med; 2010 Aug; 25(8):803-8. PubMed ID: 20237960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.
    Clarke SM; Mulcahy FM; Tjia J; Reynolds HE; Gibbons SE; Barry MG; Back DJ
    Clin Infect Dis; 2001 Nov; 33(9):1595-7. PubMed ID: 11568856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychoeducational group approach: HIV risk reduction in drug users.
    Sorensen JL; London J; Heitzmann C; Gibson DR; Morales ES; Dumontet R; Acree M
    AIDS Educ Prev; 1994 Apr; 6(2):95-112. PubMed ID: 8018443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of harm reduction in preventing HIV among injecting drug users.
    Wodak A; Maher L
    N S W Public Health Bull; 2010; 21(3-4):69-73. PubMed ID: 20513304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system.
    Mojtahedzadeh V; Razani N; Malekinejad M; Vazirian M; Shoaee S; Saberi Zafarghandi MB; Hernandez AL; Mandel JS
    AIDS Behav; 2008 Jul; 12(4 Suppl):S7-12. PubMed ID: 18521737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV risk behavior among injection drug users in Tehran, Iran.
    Razani N; Mohraz M; Kheirandish P; Malekinejad M; Malekafzali H; Mokri A; McFarland W; Rutherford G
    Addiction; 2007 Sep; 102(9):1472-82. PubMed ID: 17645427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in injection-related HIV risk after 6 months in a low-threshold methadone treatment program.
    Millson P; Challacombe L; Villeneuve PJ; Strike CJ; Fischer B; Myers T; Shore R; Hopkins S
    AIDS Educ Prev; 2007 Apr; 19(2):124-36. PubMed ID: 17411415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Implementation of a continuum of care for people living with HIV/AIDS in Hanoi (Vietnam)].
    de Loenzien M
    Sante; 2009; 19(3):141-8. PubMed ID: 20185390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.